0000792935 false 2021 FY --12-31 0000792935 2021-01-01 2021-12-31 0000792935 2021-06-30 0000792935 2022-04-13 0000792935 2021-12-31 0000792935 2020-12-31 0000792935 us-gaap:SeriesBPreferredStockMember 2020-12-31 0000792935 us-gaap:SeriesAPreferredStockMember 2020-12-31 0000792935 2020-01-01 2020-12-31 0000792935 grst:SeriesAPreferredStocksMember 2019-12-31 0000792935 us-gaap:CommonStockMember 2019-12-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000792935 grst:DiscountToParValueMember 2019-12-31 0000792935 us-gaap:ComprehensiveIncomeMember 2019-12-31 0000792935 us-gaap:RetainedEarningsMember 2019-12-31 0000792935 us-gaap:NoncontrollingInterestMember 2019-12-31 0000792935 2019-12-31 0000792935 grst:SeriesAPreferredStocksMember 2020-12-31 0000792935 us-gaap:CommonStockMember 2020-12-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000792935 grst:DiscountToParValueMember 2020-12-31 0000792935 us-gaap:ComprehensiveIncomeMember 2020-12-31 0000792935 us-gaap:RetainedEarningsMember 2020-12-31 0000792935 us-gaap:NoncontrollingInterestMember 2020-12-31 0000792935 grst:SeriesAPreferredStocksMember 2020-01-01 2020-12-31 0000792935 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000792935 grst:DiscountToParValueMember 2020-01-01 2020-12-31 0000792935 us-gaap:ComprehensiveIncomeMember 2020-01-01 2020-12-31 0000792935 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000792935 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0000792935 grst:SeriesAPreferredStocksMember 2021-01-01 2021-12-31 0000792935 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000792935 grst:DiscountToParValueMember 2021-01-01 2021-12-31 0000792935 us-gaap:ComprehensiveIncomeMember 2021-01-01 2021-12-31 0000792935 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000792935 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0000792935 grst:SeriesAPreferredStocksMember 2021-12-31 0000792935 us-gaap:CommonStockMember 2021-12-31 0000792935 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000792935 grst:DiscountToParValueMember 2021-12-31 0000792935 us-gaap:ComprehensiveIncomeMember 2021-12-31 0000792935 us-gaap:RetainedEarningsMember 2021-12-31 0000792935 us-gaap:NoncontrollingInterestMember 2021-12-31 0000792935 2021-07-01 2021-12-31 0000792935 2020-07-01 2020-12-31 0000792935 us-gaap:LandMember 2021-12-31 0000792935 us-gaap:LandMember 2020-12-31 0000792935 us-gaap:PropertyPlantAndEquipmentMember 2021-12-31 0000792935 us-gaap:PropertyPlantAndEquipmentMember 2020-12-31 0000792935 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000792935 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000792935 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000792935 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000792935 us-gaap:VehiclesMember 2021-12-31 0000792935 us-gaap:VehiclesMember 2020-12-31 0000792935 us-gaap:ComputerEquipmentMember 2021-12-31 0000792935 us-gaap:ComputerEquipmentMember 2020-12-31 0000792935 grst:LeoniteCapitalLLCMember 2021-01-01 2021-12-31 0000792935 grst:LeoniteCapitalLLCMember 2021-12-31 0000792935 grst:LeoniteCapitalLLCMember 2020-12-31 0000792935 grst:LeoniteCapitalLLC2Member 2021-01-01 2021-12-31 0000792935 grst:LeoniteCapitalLLC2Member 2021-12-31 0000792935 grst:LeoniteCapitalLLC2Member 2020-12-31 0000792935 grst:FirstFireGlobalOpportunitiesFundMember 2021-01-01 2021-12-31 0000792935 grst:FirstFireGlobalOpportunitiesFundMember 2021-12-31 0000792935 grst:FirstFireGlobalOpportunitiesFundMember 2020-12-31 0000792935 grst:AuctusFundllcMember 2021-01-01 2021-12-31 0000792935 grst:AuctusFundllcMember 2021-12-31 0000792935 grst:AuctusFundllcMember 2020-12-31 0000792935 grst:AuctusFundllc2Member 2021-01-01 2021-12-31 0000792935 grst:AuctusFundllc2Member 2021-12-31 0000792935 grst:AuctusFundllc2Member 2020-12-31 0000792935 grst:LabrysFundlpMember 2021-01-01 2021-12-31 0000792935 grst:LabrysFundlpMember 2021-12-31 0000792935 grst:LabrysFundlpMember 2020-12-31 0000792935 grst:LabrysFundlp2Member 2021-01-01 2021-12-31 0000792935 grst:LabrysFundlp2Member 2021-12-31 0000792935 grst:LabrysFundlp2Member 2020-12-31 0000792935 grst:LabrysFundlp3Member 2021-01-01 2021-12-31 0000792935 grst:LabrysFundlp3Member 2021-12-31 0000792935 grst:LabrysFundlp3Member 2020-12-31 0000792935 grst:EdBlasiakMember 2021-01-01 2021-12-31 0000792935 grst:EdBlasiakMember 2021-12-31 0000792935 grst:EdBlasiakMember 2020-12-31 0000792935 grst:JoshuaBaumanMember 2021-01-01 2021-12-31 0000792935 grst:JoshuaBaumanMember 2021-12-31 0000792935 grst:JoshuaBaumanMember 2020-12-31 0000792935 grst:JoshuaBauman2Member 2021-01-01 2021-12-31 0000792935 grst:JoshuaBauman2Member 2021-12-31 0000792935 grst:JoshuaBauman2Member 2020-12-31 0000792935 grst:GenevaRothRemarkHoldingsIncMember 2021-01-01 2021-12-31 0000792935 grst:GenevaRothRemarkHoldingsIncMember 2021-12-31 0000792935 grst:GenevaRothRemarkHoldingsIncMember 2020-12-31 0000792935 grst:GenevaRothRemarkHoldingsInc2Member 2021-01-01 2021-12-31 0000792935 grst:GenevaRothRemarkHoldingsInc2Member 2021-12-31 0000792935 grst:GenevaRothRemarkHoldingsInc2Member 2020-12-31 0000792935 grst:GenevaRothRemarkHoldingsInc3Member 2021-01-01 2021-12-31 0000792935 grst:GenevaRothRemarkHoldingsInc3Member 2021-12-31 0000792935 grst:GenevaRothRemarkHoldingsInc3Member 2020-12-31 0000792935 grst:GenevaRothRemarkHoldingsInc4Member 2021-01-01 2021-12-31 0000792935 grst:GenevaRothRemarkHoldingsInc4Member 2021-12-31 0000792935 grst:GenevaRothRemarkHoldingsInc4Member 2020-12-31 0000792935 grst:SeriesNMember 2021-01-01 2021-12-31 0000792935 grst:SeriesNMember 2021-12-31 0000792935 grst:SeriesNMember 2020-12-31 0000792935 grst:CranberryCoveHoldingsLtdMember 2021-12-31 0000792935 grst:CranberryCoveHoldingsLtdMember 2021-01-01 2021-12-31 0000792935 grst:CranberryCoveHoldingsLtdMember 2020-12-31 0000792935 srt:MinimumMember 2021-01-01 2021-12-31 0000792935 srt:MaximumMember 2021-01-01 2021-12-31 0000792935 grst:ShawnLeonMember 2021-12-31 0000792935 grst:ShawnLeonMember 2020-12-31 0000792935 grst:ShawnLeonMember 2021-01-01 2021-12-31 0000792935 grst:EileenGreeneMember 2021-12-31 0000792935 grst:EileenGreeneMember 2020-12-31 0000792935 grst:WarrantsMember 2019-12-31 0000792935 grst:WarrantsMember 2020-01-01 2020-12-31 0000792935 grst:WarrantsMember 2020-12-31 0000792935 grst:WarrantsMember 2021-01-01 2021-12-31 0000792935 grst:WarrantsMember 2021-12-31 0000792935 srt:MaximumMember 2021-12-31 0000792935 srt:MinimumMember 2021-12-31 0000792935 grst:Excercise1Member 2021-12-31 0000792935 grst:Excercise2Member 2021-12-31 0000792935 grst:Excercise3Member 2021-12-31 0000792935 grst:RentalOperationsMember 2021-01-01 2021-12-31 0000792935 grst:InPatientServicesMember 2021-01-01 2021-12-31 0000792935 grst:TotalMember 2021-01-01 2021-12-31 0000792935 grst:RentalOperationsMember 2021-12-31 0000792935 grst:InPatientServicesMember 2021-12-31 0000792935 grst:TotalMember 2021-12-31 0000792935 grst:RentalOperationsMember 2020-01-01 2020-12-31 0000792935 grst:InPatientServicesMember 2020-01-01 2020-12-31 0000792935 grst:TotalMember 2020-01-01 2020-12-31 0000792935 grst:RentalOperationsMember 2020-12-31 0000792935 grst:InPatientServicesMember 2020-12-31 0000792935 grst:TotalMember 2020-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

  ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended: December 31, 2021

 

or

 

 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from  to  

 

Commission file number: 000-15078

 

Ethema Health Corporation

 

(Exact name of registrant as specified in its charter)

 

Colorado 84-1227328

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

1590 S. Congress Avenue

West Palm Beach, Florida 33406

(Address of principal executive offices)

 

(561) 290-0239

(Registrant’s telephone number, including area code)

  

Securities registered under Section 12(b) of the Exchange Act: 
 
Title of each class Name of each exchange on which registered
   
None N/A

 

Securities registered under Section 12(g) of the Act:

 

Common Stock, $0.01 par value per share

(Title of class) 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  ☐  No  ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  ☐  No  ☒ 

 

Indicate by check mark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒  Yes  No  ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every interactive data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒  No  ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of issuer’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

 

 
 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated file, a non-accelerated file, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer Accelerated filer
Non-accelerated filer ☐  (Do not check if a smaller reporting company) Smaller reporting company
  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ☐  No  ☒

 

The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant as of June 30, 2021, based on a closing share price of $0.0044 was approximately $12,207,271.

 

As of April 13, 2022, the registrant had 3,729,053,805 shares of its common stock, par value $0.01 per share, outstanding.

 

 

 

 
 

 

ETHEMA HEALTH CORPORATION  

YEAR ENDED DECEMBER 31, 2021

TABLE OF CONTENTS

 

    PAGE
PART I.      
Item 1. Business 1  
Item 1A. Risk Factors 4  
Item 1B. Unresolved  Staff Comments 4  
Item 2. Properties 4  
Item 3. Legal Proceedings 4  
Item 4. Mine Safety Disclosures 4  
   
PART II.      
Item 5. Market for Registrant’s Common Equity Related Stockholder Matters and Issuer Purchases of Equity Securities 5  
Item 6. Reserved 7  
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of  Operations 7  
Item 8. Financial Statements and  Supplementary Data 10  
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 11  
Item 9A. Controls and Procedures 11  
Item 9B. Other Information 11  
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 11  
       
PART III      
Item 10. Directors, Executive Officers and Corporate Governance 12  
Item 11. Executive  Compensation 13  
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 14  
Item 13. Certain Relationships and Related Transactions, and Director Independence 15  
Item 14. Principal Accountant Fees and Services 15  
Part IV.      
Item 15. Exhibits and Financial Statements Schedules 17  
SIGNATURES 20  

 


 
 

 

PART I

Item 1. Business.

 

Company History

Ethema Health Corporation (the “Company” or “Ethema”), a Colorado corporation was incorporated under the laws of the State of Colorado on April 1, 1993, and is the surviving company of a merger, effective February 1, 1995, between the Company and Nova Natural Resources Corporation, a Delaware corporation (“Nova Delaware”). The merger was effectuated solely for the purpose of changing the Company’s domicile from Delaware to Colorado. At all times prior to 2001, the Company was engaged in the oil and gas exploration business. Nova Delaware was the successor entity to Nova Petroleum Corporation, a Delaware corporation, and Power Resources Corporation, a Delaware corporation, which merged in 1986 (“the 1986 Merger”). Prior to the 1986 Merger, Nova Petroleum Corporation and Power Resources Corporation had operated since 1979 and 1972, respectively. In 2001, the Company entered into the electronics business and this business was active in 2001 and 2002, as part of the Torita Group. After 2002, the Company continued with various stages of development in this business until 2010.

 

On April 1, 2010, the Company changed its principal operations from development stage electronics to healthcare services. On March 29, 2010, the Company entered into a one year consulting agreement with GreeneStone Clinic Inc., a Canadian corporation (“Greenestone Clinic”), whereby Greenestone Clinic provided consulting services for the Company’s development and operation of medical clinics in the province of Ontario, Canada. Specifically, Greenestone Clinic provided medical and business expertise in the initial startup of private clinics and technical assistance to ensure that the clinics were in compliance with governmental policy and procedure requirements as well as any operational requirements. At the time of entering into this consulting agreement, Greenestone Clinic operated a clinic at the Muskoka property housing its addiction treatment clinic and provided endoscopy services. The Company started offering medical services in June 2010, offering various medical services, including endoscopy, cardiology and executive medicals, which services were subsequently sold.

 

On May 15, 2010, the Company secured a sublease of space (which was previously the Rothbart Pain Clinic) of approximately 8,000 sq. ft. to be used as the Company’s executive offices and to run an endoscopy clinic. The Endoscopy clinic was subsequently sold. The Company, through its wholly owned subsidiary GreeneStone Clinic Muskoka Inc. (“GreeneStone Muskoka”), also entered into a lease with the owner of the Muskoka premises on April 1, 2011 and provided mental health and addiction treatment services and operated an in-patient addiction treatment center at this location.

 

During December 2016, the Company obtained a license to operate and provide addiction treatment healthcare services in Florida, USA. The company commenced operations under this license with effect from January 2017.

 

On February 14, 2017, the Company completed a series of transactions (referred to collectively as the “Restructuring Transactions”), including a Share Purchase Agreement (the “SPA”) whereby the Company acquired 100% of the stock of Cranberry Cove Holdings Ltd. (“CCH”), which held the real estate on which the Company’s GreeneStone Muskoka operated, an asset purchase agreement (the “APA”) and lease (the “Lease”) whereby the Company sold certain of the GreeneStone Muskoka business assets and leased the real estate to the buyer, and a real estate purchase agreement and asset purchase agreement whereby the Company purchased the real estate and business assets of Seastone Delray (the “Florida Purchase”).

 

The Share Purchase Agreement

Under the SPA, the Company acquired 100% of the stock of CCH from Leon Developments Ltd. (“Leon Developments”), a company wholly owned by Shawn E. Leon, who is the President, CEO, and CFO of the Company (“Mr. Leon”). CCH owns the real estate on which GreeneStone Muskoka is located. The total consideration paid by the Company was CDN$3,517,062, including the assumption of certain liabilities of CCH, which was funded by the assignment to Leon Developments of certain indebtedness owing to the Company in the amount of CDN$659,918, and the issuance of 60,000,000 shares of the Company’s common stock to Leon Developments, valued at US$0.0364 per share.

  1  

 

 

The Asset Purchase Agreement and Lease

Under the APA, the assets of GreeneStone Muskoka were sold by the Company, through its subsidiary, GreeneStone Muskoka, to Canadian Addiction Residential Treatment LP (the “Purchaser” or “CART”), for a total consideration of CDN$10,000,000. The proceeds of the GreeneStone Muskoka asset sale were used to pay down certain tax debts and operational costs of the Company and to fund the Florida Purchase, mentioned below.

 

Through the APA, substantially all of the assets of GreeneStone Muskoka were sold, leaving Ethema with only the underlying clinic real estate, which the Company, through its newly acquired subsidiary, CCH concurrently leased to the Purchaser. The Lease is a triple net lease and provides for a five (5) year primary term with three (3) five-year renewal options, annual base rent for the first year at CDN$420,000 with annual increases, an option to tenant to purchase the leased premises and certain first refusal rights.

 

The Florida Purchases and Business

 

Immediately after closing on the sale of the assets of GreeneStone Muskoka, the Company closed on the acquisition of the business and real estate assets of Seastone Delray pursuant to certain real estate and asset purchase agreements. This business is operated through its wholly owned subsidiary, Addiction Recovery Institute of America, LLC (“ARIA”). The purchase price for the ARIA assets was US$6,070,000 financed with a purchase money mortgage of US$3,000,000, and US$3,070,000 in cash.

 

On April 4, 2017 the Company changed its Corporate name from Greenestone Healthcare Corporation to Ethema Health Corporation.

 

On November 2, 2017, the Company entered into an Agreement to purchase from AREP 5400 East Avenue LLC (“the Landlord”) certain buildings in West Palm Beach, Florida, totaling approximately 80,000 square feet, on which the Company planned to operate a substance abuse treatment center. The purchase price of the Property was $20,530,000. The Company made a series of nonrefundable down payments totaling $2,940,546 in 2017 and 2018. The Company could not get the necessary financing to close on the deal.

 

On May 23, 2018, the Company converted the agreement to purchase the buildings from the Landlord into a real property lease agreement with a purchase option. The lease was for an initial 10 years and provided for two additional 10 year extensions.

 

In June 2018, the Company moved its ARIA operations into the West Palm Beach properties and in September 2018 received a license to operate in-patient detoxification and residential treatment services.

 

In June of 2019, the Company and the Landlord wished to proceed with marketing the property for sale and agreed to convert the long term lease into a month to month lease for a reduced amount of space.

 

The Company once again had an opportunity to purchase the property in October of 2019 but could not arrange for sufficient financing to complete the purchase and the Landlord subsequently entered into a conditional agreement with another purchaser and on December 20, 2019, the Company entered into an agreement with the landlord to terminate the lease agreement on January 31, 2020.

 

  2  

 

On June 30, 2020, the Company entered into an agreement (“the Stock Purchase Agreement”), whereby the Company agreed to acquire 51% of American Treatment Holdings, Inc. (“ATHI”) from The Q Global Trust (“Seller”) and Lawrence B Hawkins (“Hawkins”), which owned 100% of Evernia Health Services LLC. (“Evernia”), which operates drug rehabilitation facilities. The consideration for the acquisition was a loan to be provided by the Company to Evernia in the amount of $500,000.

 

The Company originally had a 180 day option, to purchase an additional 9% of ETHI for a purchase consideration of $50,000. On April 28, 2021, the Stock Purchase Agreement was amended whereby the option to purchase an additional 9% of ATHI for $50,000 was amended to purchase an additional 24%, an increase of 15% over the prior option, for 100,000,000 shares of common stock and $50,000. The remaining condition to closing, the receipt of approval for the change of ownership of the license from the Department of Children and Family Services of Florida, was satisfied by probationary approval, which was received on June 30, 2021. The Company exercised the option and issued the 100,000,000 shares of common stock, resulting in the Company owning 75% of ATHI..

 

Corporate Structure

 

The Company consists of the following entities:

 

  · Ethema Health Corporation (Parent company);

 

Ethema is the publicly traded investment holding company, registered in Colorado, U.S.

 

  · Cranberry Cove Holdings, Ltd, a Canadian registered company (wholly owned);

 

CCH owns and leases the property on which CART operates an addiction treatment center.

 

  · Addiction Recovery Institute of America, LLC, a US registered company (wholly owned);

 

ARIA operated a treatment center in Delray Beach, Florida out of premises which it had acquired in February 2017. The treatment center was relocated and was operated out of leased premises in West Palm Beach Florida.

 

  · Delray Andrews RE, LLC (“DARE”), a US registered company (wholly owned and dormant);

 

DARE has remained dormant since inception.

 

  · GreeneStone Clinic Muskoka Inc., a Canadian registered company (wholly owned);

 

Muskoka previously owned and operated the addiction treatment center in Canada which was sold to CART.

 

  · American Treatment Holdings, Inc, a US registered company (75% owned);

 

ATHI owns 100% of the members interest of Evernia. Ethema has been financing the operations of Evernia since June 2020.

 

  · Evernia Health Center, a US registered company.

 

Evernia operates a treatment center in West Palm Beach Florida and is a wholly owned subsidiary of ATHI which was acquired by Ethema effective July 1, 2021. The Company has been actively involved in the operation of this treatment center since June 30, 2020.

 

Employees

 

As of December 31, 2021, Ethema had 46 employees.

 

  3  

 

Marketing

 

The addiction treatment business in the USA operates as an insured healthcare service. Our marketing efforts are long-term processes of establishing relationships with relevant professionals and our treatment staff. We use industry specific conferences and functions to network with these professionals.

 

Through Evernia, the Company has an in-network relationship with a single large health care provider and the majority of the Company’s clients are sourced from this health care provider.

 

Competition

 

There are a significant amount of treatment facilities in the United States, we compete with these clinics for patients who are typically covered by insured healthcare services.

 

Environmental Regulations

 

The Company is not currently subject to any pending administrative or judicial enforcement proceedings arising under environmental laws or regulations. Environmental laws and regulations may be adopted in the future which may have an impact upon the Company’s operations.

 

Item 1A. Risk Factors.

 

Not applicable because we are a smaller reporting company.

 

Item 1B. Unresolved Staff Comments

 

None. 

 

Item 2. Properties.

 

Ethema Executive Offices

 

The Company’s executive offices are located at 1590 S. Congress Avenue, West Palm Beach, Florida, 33406.

 

West Palm Beach Treatment Operations

 

The Company, through its acquisition of ATHI, effectively acquired a 75% of the Evernia treatment facility located at 950 Evernia Street, West Palm Beach Florida. The Company has been actively involved in the operation of the Evernia treatment facility since June 2020.

 

Muskoka Treatment Facility

 

The Muskoka Treatment Facility is located in Bala, Ontario, 3571 Highway 169. The property is 43 acres and contains approximately 48,000 square feet of buildings. The property is wholly owned by CCH and has been leased to CART for an initial term of five years, which ended on February 28, 2022. The tenant exercised its option to extend the lease term for an additional five years. The lease gives the tenant an option to extend for two additional five (5) year terms, an option to purchase the property at any time for a purchase price of CDN$7,000,000 in the first thirty six (36) months of the term and thereafter at a purchase price increased by CDN$1,500,000 for each successive year up to a maximum of CDN$10,000,000, and a right of first refusal in the event of a sale to a third party.

 

Item 3. Legal Proceedings.

 

A suit, claiming past due rent was filed against the Company in March 2020 for rent of a storage warehouse, the warehouse was abandoned during March 2020. The rental expense was accrued in our records for $12,293 as of December 31, 2021.

 

Other than disclosed above, we are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

Item 4. Mine Safety Disclosures.

 

None.

 

 

  4  

 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities .

 

  (a) Market Information

 

The Company’s common stock is quoted on the Over-the-counter Market (the “OTC PINK”) under the symbol “GRST”. The Company was sponsored by the market maker Wilson Davis & Co. from Salt Lake City, Utah, which filed a Form 15c2-11 application with the Financial Industry Regulatory Authority (“FINRA”) for the Company in 2011. This application was approved by FINRA in February 2012, and Wilson Davis & Co. first quoted the stock in March 2012.

 

From March 2012 to January 2020, our common stock had been traded on the OTCQB markets under the symbol “GRST”, in January 2020, the stock was downgraded to the OTC Pink Sheets market.

 

The last reported sale price of our common stock on the OTC Pink on April 13, 2022, was $0.0007 per share. As of April 13, 2022, there were approximately 155 holders of record of our common stock. 

 

Dividend Policy

 

We have not paid any cash dividends on our common stock to date, and we have no intention of paying cash dividends in the foreseeable future. Whether we declare and pay dividends is determined by our Board of Directors at their discretion, subject to certain limitations imposed under Colorado corporate law. The timing, amount and form of dividends, if any, will depend on, among other things, our results of operations, financial condition, cash requirements and other factors deemed relevant by our Board of Directors.

 

Equity Compensation Plan Information

 

See Item 11 - Executive Compensation for equity compensation plan information.

 

Recent Sales of Unregistered Securities

 

Other than as set forth below or as previously disclosed in our filings with the Securities and Exchange Commission, we did not sell any equity securities during the year ended December 31, 2021 in transactions that were not registered under the Securities Act.

 

On January 8, 2021, the Company issued 78,763,466 shares of common stock to Leonite Capital, LP (“Leonite”), in connection with a conversion notice received, converting principal and interest of $70,137.

 

On March 3, 2021, the Company issued 97,000,000 shares of common stock to Leonite in connection with a conversion notice received, converting principal and interest of $95,000.

 

On March 9, 2021, the Company received notification of exercise of warrants for 66,666,666 shares on a cashless basis from Auctus Fund, LLC (“Auctus”), resulting in the issuance of 59,999,999 shares of common stock valued on the date of issuance at $90,000.

 

On May 3, 2021, the Company issued 100,000,000 shares of common stock to Labrys Fund LP (“Labrys”) in connection with a conversion notice received, converting principal and interest of $90,000.

 

On May 13 2021, the Company received notification of exercise of warrants for 50,505,051 shares on a cashless basis from First Fire Global Opportunities Fund, resulting in the issuance of 42,353,038 shares of common stock valued on the date of issuance at $86,824.

 

 On June 1, 2021, the Company issued 30,000,000 shares of common stock to Leonite in connection with a conversion notice received, converting principal and interest of $29,250.

 

On June 8, 2021, the Company issued 106,313,288 shares of common stock to Joshua Bauman in connection with a conversion notice received, converting principal and interest of $105,563.

 

On June 10, 2021, the Company issued 60,000,000 shares of common stock to Leonite in connection with a conversion notice received, converting principal and interest of $59,250.

 

On July 1, 2021, in terms of the amendment to the stock Purchase Agreement entered into on June 30, 2020 between the Company, the Q Global Trust, LLC, and American Treatment Holdings, the Company issued 100,000,000 shares of common stock thereby closing the transaction and acquiring a 75% interest in ATHI.

 

  5  

 

 

On July 7, 2021, in terms of a conversion notice received by the Company, Labrys converted the aggregate principal sum of $100,800 into 112,000,000 shares of common stock.

 

On August 6, 2021, the Company received a cashless warrant exercise from Labrys, exercising warrants for 100,000,000 shares, resulting in the issuance of 86,333,333 shares of common stock valued on the date of issuance at $176,983.

 

On September 10, 2021, the Company issued 59,259,630 shares of common stock to Leonite in connection with a conversion notice received, converting principal and interest of $60,977.

 

On September 24, 2021, the company received a cashless warrant exercise from Labrys, exercising warrants for 91,666,666 shares, resulting in the issuance of 54,999,999 shares of common stock valued on the date of issuance at $242,000.

 

On September 24, 2021, the company received a cashless warrant exercise from Labrys, exercising warrants for 60,000,000 shares, resulting in the issuance of 36,939,393 shares of common stock valued on the date of issuance at $162,533.

 

On September 28, 2021, the Company issued 60,000,000 shares of common stock to Labrys in connection with a conversion notice received, converting principal of $54,000.

 

On October 8, 2021, in terms of a conversion notice received by the company, Labrys converted the aggregate principal sum of $55,800 into 62,000,000 shares of common stock.

 

On October 15, 2021, in terms of a conversion notice received by the company, Labrys converted the aggregate principal sum of $7,400 into 8,222,222 shares of common stock.

 

On October 19, 2021, the Company issued 50,496,728 shares of common stock to Leonite in connection with a conversion notice received, converting principal and interest of $49,747.

 

On October 25, 2021, the Company issued 39,405,310 shares of common stock to Joshua Bauman in connection with a conversion notice received, converting principal and interest of $38,655.

 

On October 29, 2021, the Company issued 83,771,947 shares of common stock to Leonite in connection with a conversion notice received, converting principal and interest of $83,022.

 

On November 22, 2021, the Company issued 58,427,091 shares of common stock to Leonite in connection with a conversion notice received, converting principal and interest of $57,677.

 

On November 23, 2021, in terms of a conversion notice received by the company, Labrys converted the aggregate principal sum of $6,329 and interest of $60,500 into 75,000,000 shares of common stock.

 

On December 13, 2021, in terms of a conversion notice received by the company, Leonite converted the aggregate principal and interest amount of $89,933 into 90,682,696 shares of common stock.

 

Penny Stock

 

The U.S. Securities and Exchange Commission (the “SEC”) has adopted rules that regulate broker dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a market price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. The penny stock rules require a broker dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains a description of the broker’s or dealer’s duties to the customer and of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of the securities laws. (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including language, type size and format, as the SEC shall require by rule or regulation.

 

The broker dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations for the penny stock; (b) the compensation of the broker dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statement showing the market value of each penny stock held in the customer’s account.

 

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written acknowledgment of the receipt of a risk disclosure statement, a written agreement as to transactions involving penny stocks, and a signed and dated copy of a written suitability statement.

 

These disclosure requirements may have the effect of reducing the trading activity for our common stock. Therefore, stockholders may have difficulty selling our securities.

 

 

  6  

 

 

Item 6. Reserved

 

Special Note Regarding Forward-Looking Statements 

 

Many of the matters discussed within this Annual Report contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) on our current expectations and projections about future events. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based on our current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed, projected or implied in or by the forward-looking statements. Such risks and uncertainties include the risks noted under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” but are also contained elsewhere. We do not undertake any obligation to update any forward looking statements. Unless the context requires otherwise, references to “we,” “us,” “our,” and “Ethema,” refer to Ethema Health Corporation and its subsidiaries.

 

Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We do not undertake any obligation to update any forward-looking statements.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 

 

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments, and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments, and assumptions are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our consolidated financial statements would be affected to the extent there are material differences between these estimates. This discussion and analysis should be read in conjunction with the company’s consolidated financial statements and accompanying notes to the consolidated financial statements for the year ended December 31, 2021.

 

Results of operations for the year ended December 31, 2021 and the year ended December 31, 2020.

 

Revenue

 

Revenue was $1,942,588 and $338,996 for the years ended December 31, 2021 and 2020, respectively, an increase of $1,603,592 or 473.0%.

 

Revenue from patient treatment was $1,568,071 and $0 for the years ended December 31, 2021 and 2020, respectively, an increase of $1,568,071 or 100.0%. The increase is due to the acquisition of Evernia, a West Palm Beach based treatment facility, on July 1, 2021.

 

Revenue from rental income was $374,517 and $338,996 for the years ended December 31, 2021 and 2020, respectively, an increase of $35,521 or 10.5%, the increase is primarily due to the contractual increase in rental income..

 

Operating Expenses

 

Operating expenses was $1,940,483 and $502,340 for the years ended December 31, 2021 and 2020, respectively, an increase of $1,438,143 or 286.3%. The increase in operating expenses is attributable to:

 

General and administrative expenses of $531,391 and $55,756 for the years ended December 31, 2021 and 2020, respectively, an increase of $475,635 or 853.1%. The increase is due to the acquisition of the Evernia treatment facility effective July 1, 2021, including contractor costs of $198,526, advertising costs of $89,500 and $96,346 in meals for patients.

 

Rent expense was $178,679 and $5,512 for the years ended December 31, 2021 and 2020, an increase of $173,167 or 3,141.6%, due to the acquisition of Evernia, effective July 1, 2021, which leases a property in West Palm Beach, Florida.

 

Management fees was $60,000 and $0 for the years ended December 31, 2021 and 2020, respectively, an increase of $60,000 or 100.0%. Management fees for the current period represent management fees paid to the minority holder in ATHI.
  7  

 

Professional fees were $132,275 and $231,264 for the years ended December 31, 2021 and 2020, respectively, a decrease of $98,989 or 42.8%. The decrease is primarily due to consulting fees that were paid to two individuals in the prior year who had assisted with business development efforts.

 

Salaries and wages was $712,787 and $88,532 for the years ended December 31, 2021 and 2020, respectively, an increase of $624,255 or 705.1%. The increase is due to the acquisition of the Evernia treatment facility effective July 1, 2021.

 

Depreciation expense was $325,351 and $121,276 for the years ended December 31, 2021 and 2020, respectively, an increase of $204,075 or 168.3%. The increase in the depreciation charge was due to the acquisition of Evernia, including the amortization of the health care provider license amounting to $178,990.

 

Operating profit (loss)

 

The operating profit was $2,105 and the operating loss was $(163,344) for the years ended December 31, 2021 and 2020, respectively, an increase of $165,449 or 101.3%. The increase is attributable to the acquisition of Evernia on July 1, 2021, which resulted in increased revenue primarily due to patients obtained from the health care provider license which Evernia has secured.

 

Other income

 

Other income was $273,373 and $1,183 for the years ended December 31, 2021 and 2020, respectively. Other income includes; (i) the reversal of a $250,000 provision raised for rental expenses on a previous property leased by the Company which has, subsequently been disposed of by the Landlord, and (ii) a financial inducement granted to the Company by the Evernia landlord.

 

Forgiveness of government relief loan

 

Forgiveness of government relief loan was $156,782 and $0 for the years ended December 31, 2021 and 2020, respectively, an increase of $156,782 or 100.0%. The company had met all requirements for forgiveness of one of its Covid-19 government relief loans and the loan forgiveness was recorded during the fourth quarter.

 

Gain on debt extinguishment

 

Gain on debt extinguishment was $0 and $12,601,823 for the years ended December 31, 2021 and 2020, respectively. In the prior year, the company entered into several debt extinguishment agreements with convertible debt holders whereby the amounts payable and the payment terms under these convertible notes were renegotiated, this also resulted in the extinguishment of derivative liabilities related to these convertible notes.

 

Gain on sale of assets

 

The Gain on sale of assets was $0 and $36,470 for the years ended December 31, 2021 and 2020, respectively. The gain in the prior year represented an over-accrual for expenses relating to the disposal of the Delray Beach properties.

 

Loss on advance

Loss on advance was $120,000 and $0 for the years ended December 31, 2021 and 2020, respectively, an increase of $120,000 or 100.0%. The company advanced funds to Local link wellness in the prior year, which were deemed to be uncollectible in 2021.

 

Warrants exercised

Warrant exercise was $0 and $95,868 for the years ended December 31, 2021 and 2020, respectively, a decrease of $95,868 or 100.0%. In the prior year warrants were exercised for 184,000,000 shares of common stock

 

Fair value of warrants granted to convertible debt holders

 

Fair value of warrants granted to convertible debt holders was $854,140 and $0 for the years ended December 31, 2021 and 2020, an increase of $854,140 or 100%. The Company granted warrants to certain convertible debt holders in terms of agreements entered into with them, whereby any debt issued subsequent to their debt on more favorable terms would result in the debt holders being entitled to the same terms as issued to the subsequent debt holders. The company issued warrants for a total of 195,963,598 shares of common stock which was valued using a Black Scholes valuation model.

 

Penalty on convertible notes

 

Penalty on convertible notes was $9,240 and $0 for the years ended December 31, 2021 and 2020, an increase of $9,240. The penalty on convertible notes relates to a fee paid for the extension of repayment dates on the Labrys note.

 

Interest income 

Interest income was $0 and $629 for the years ended December 31, 2021 and 2020 respectively, a decrease of $629 or 100.0%. The interest income is immaterial.

 

  8  

 

 

Interest expense

 

Interest expense was $829,525 and $676,634 for the years ended December 31, 2021 and 2020, respectively, an increase of $152,891 or 22.6%, primarily due to the increase in convertible note funding during the current year.

 

Debt discount

 

Debt discount was $1,965,551 and $861,657 for the years ended December 31, 2021 and 2020, respectively, an increase of $1,103,894 or 128.1%. The increase is primarily due to new convertible notes issued during the current year and the amortization of loans entered into during the second half of the prior year.

 

Derivative liability movement

 

The derivative liability movement during the current year represents the mark to market movements of variably priced convertible notes and warrants issued during the current and prior years. These securities are marked to market on a quarterly basis and the resultant gain or loss is recorded as a derivative liability movement in the consolidated statements of operations and comprehensive loss.

 

Foreign exchange movements

 

Foreign exchange movements was $(34,301) and $(175,500) for the years ended December 31, 2021 and 2020, respectively and represents the realized exchange gains and (losses) on monetary assets and liabilities settled during the current year as well as mark to market adjustments on monetary assets and liabilities reflected on the balance sheet and denominated in Canadian Dollars.

 

Net (loss) income before taxation

 

Net loss was $(1,854,306) and net income was $3,084,992 for the years ended December 31, 2021 and 2020, respectively, a decrease of $4,939,298 or 160.1%. The decrease is primarily due to the fair value of the warrants granted, the debt discount amortization, and the prior year gain on debt extinguishment, offset by the derivative liability movements, as discussed above.

 

Taxation

Taxation credit was $280,903 and $0 for the years ended December 31, 2021 and 2020, respectively an increase of $280,903 or 100.0%. the tax credit arose due to the reversal of prior years’ accrual for $250,000 in penalty tax for non-disclosure of foreign entities in the US tax return, a deferred tax movement of $37,588 on the amortization of licenses which arose on the acquisition of ATHI and Evernia, and a small tax provision on profits realized on the ATHI and Evernia results.

 

Net (loss) income

 

Net loss was $(1,573,403) and net income was $3,084,992 for the years ended December 31, 2021 and 2020, respectively, a decrease of $4,658,395 or 151.0%. The decrease is primarily due to the reasons discussed above.

 

Liquidity and Capital Resources

 

Cash used in operating activities was $85,567 and $101,970 for the years ended December 31, 2021 and 2020, respectively a decrease of $16,403 or 16.1%. The decrease is primarily due to the following:

 

●     The increase in net loss of $4.7 million, as discussed above.
●     The increase in non-cash movements of $5.31 million, primarily due to the movement on the gain on debt extinguishment of $12.6 million, the increase in the movement on the amortization of debt discount of $1,1 million, and the increase in the movement of fair value of warrants granted of $0.9 million, offset by the net movement in derivative liabilities of $9.1 million.
●     The absorption of cash into working capital of $0.6 million during the current year, primarily due to the acquisition of Evernia and ATHI on July 1, 2021.

 

Cash used in investing activities was $0.6 million and $0.7 million for the years ended December 31, 2021 and 2020, respectively. We invested $0.5 million (2020 - $0.7 million) in the Evernia treatment facility based in West Palm Beach, prior to acquisition. We also purchased property and equipment of $0.1million, primarily to support the Evernia operation during the current year.

 

Cash generated by financing activities was $0.6 million and $0.9 million for the years ended December 31, 2021 and 200, respectively. During the current year we raised $1.2 million and repaid $0.5 million in convertible notes, primarily to fund the Evernia operations.

 

Over the next twelve months we estimate that the company will require approximately $6.5 million in funding to repay its obligations, if these obligations are not converted to equity and for funding working capital as we continue to seek opportunities for addiction treatment in the US markets. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. In the opinion of management, the Company’s liquidity risk is assessed as high.

 

  9  

 

 

Item 8. Financial Statements and Supplementary Data.

 

ETHEMA HEALTH CORPORATION

 

INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS 

(Expressed in US$ unless otherwise indicated)

 

  PAGE
Report of Independent Registered Public Accounting Firm (PCAOB ID 229) F-1
Consolidated Balance Sheets as of December 31, 2021 and 2020 F-2
Consolidated Statements of Operations and Comprehensive (Loss) income for the years ended December 31, 2021 and 2020 F-3
Consolidated Statements of Changes in Stockholders Deficit for the years ended December 31, 2021 and 2020 F-4
Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020 F-5
Notes to the Consolidated Financial Statements F-6

 

  10  

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and

Stockholders of Ethema Health Corporation

West Palm Beach, Florida

 

Opinion on the Consolidated Financial Statements

We have audited the accompanying balance sheets of Ethema Health Corporation (the “Company”) at December 31, 2021 and 2020, and the related consolidated statements of operations and comprehensive income (loss), changes in stockholders’ deficit, and cash flows for each of the years ended December 31, 2021 and 2020, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years ended December 31, 2021 and 2020, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

The accompanying consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 3 to the consolidated financial statements, the Company had accumulated deficit of approximately $44.7 million and negative working capital of approximately $13.2 million at December 31, 2021, which raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Critical Audit Matter

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Accounting for Embedded Conversion Features on Convertible Notes – Refer to Notes 12 and 16 to the Financial Statements

The principal considerations for our determination that performing procedures relating to the valuation of derivatives is a critical audit matter are the significant judgment by management when developing the fair value of the derivative liabilities. This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management’s significant assumptions related to the valuation models used and related variable inputs used within those models.

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing management’s process for developing the fair value estimate; evaluating the appropriateness of the valuation techniques; testing the completeness and accuracy of underlying data used in the model; and evaluating the significant assumptions used by management, including the values of expected volatility and discount rate. Evaluating management’s assumptions related to the volatility amounts and discount rates involved evaluating whether the assumptions used by management were reasonable considering the current and historical performance, the consistency with external market and industry data, and whether these assumptions were consistent with evidence obtained in other areas of the audit.

 

/s/ Daszkal Bolton LLP
   
We have served as the Company’s auditor since 2018.
   
Sunrise, Florida
   
April 14, 2022  
 229  

 

F-1

 

 

 

ETHEMA HEALTH CORPORATION

CONSOLIDATED BALANCE SHEETS

                 
    December 31, 2021   December 31, 2020
         
ASSETS    
         
Current assets                
Cash   $ 48,822     $ 90,500  
Accounts receivable, net     176,011       3,075  
Prepaid expenses     29,731       19,190  
Other current assets     17,235       131,938  
Other investments              690,449  
Total current assets     271,799       935,152  
Non-current assets                
Due on sale of subsidiary     5,115       5,094  
Property and equipment     3,012,663       2,882,220  
Intangible assets, net     1,610,913           
Right of use assets     1,653,816           
Total non-current assets     6,282,507       2,887,314  
Total assets   $ 6,554,306     $ 3,822,466  
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT                
                 
Current liabilities                
Accounts payable and accrued liabilities   $ 438,482     $ 833,615  
Taxes payable     658,836       850,277  
Convertible loans, net of discounts     4,891,938       4,200,217  
Short term loans     122,167       115,375  
Mortgage loans     3,864,312       115,704  
Government assistance loans     157,367       156,782  
Operating lease liability     241,083           
Finance lease liability     7,386           
Derivative liability     515,901       4,765,387  
Accrued dividends     105,049       15,594  
Related party payables     2,514,281       2,811,849  
Total current liabilities     13,516,802       13,864,800  
Non-current liabilities                
Government assistance loans     47,326       31,417  
Deferred taxation     273,057           
Third party loans     646,176       704,271  
Operating lease liability     1,493,431           
Finance lease liability     32,895           
Mortgage loans, net of current portion              3,848,077  
Total non-current liabilities     2,492,885       4,583,765  
Total liabilities     16,009,687       18,448,565  
                 
Preferred stock - Series B; $1.00 par value, 10,000,000 authorized, 400,000 shares outstanding as of December 31, 2021 and 2020.     400,000       400,000  
                 
Stockholders’ deficit                
Preferred stock - Series A; $0.01 par value, 10,000,000 authorized, 4,000,000 shares outstanding at December 31, 2021 and 2020.     40,000       40,000  
Common stock - $0.01 par value, 10,000,000,000 shares authorized; 3,579,053,805 and 2,207,085,665 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively.     35,790,539       20,270,857  
Additional paid-in capital     22,791,350       23,344,885  
Discount for shares issued below par value     (26,013,367 )     (17,728,779  
Accumulated other comprehensive income     816,532       806,719  
Accumulated deficit     (44,103,311 )     (42,459,781  
Stockholders’ deficit attributable to Ethema Health Corporation stockholders’     (10,678,257 )     (15,726,099  
Non-controlling interest     822,876       700,000  
Total stockholders’ deficit     (9,855,381 )     (15,026,099  
Total liabilities and stockholders’ deficit   $ 6,554,306     $ 3,822,466  

 

 

The accompanying notes are an integral part of the consolidated financial statements

 

 

F-2

 

 

ETHEMA HEALTH CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS 

AND COMPREHENSIVE (LOSS) INCOME

 

                 
    Year ended
December 31, 2021
  Year ended
December 31, 2020
         
Revenues   $ 1,942,588     $ 338,996  
                 
Operating expenses                
General and administrative     531,391       55,756  
Rent expense     178,679       5,512  
Management fees     60,000           
Professional fees     132,275       231,264  
Salaries and wages     712,787       88,532  
Depreciation expense     325,351       121,276  
Total operating expenses     1,940,483       502,340  
                 
Operating profit (loss)     2,105       (163,344 )
                 
Other (expense) income                
Other income     273,373       1,183  
Forgiveness of government relief loan     156,782           
Gain on debt extinguishment              12,601,823  
Gain on sale of assets              36,470  
Loss on advance     (120,000 )         
Warrants exercised              (95,868 )
Fair value of warrants granted to convertible note holders     (854,140 )         
Penalty on convertible notes     (9,240 )         
Interest income              629  
Interest expense     (829,525 )     (676,634 )
Debt discount     (1,965,551 )     (861,657 )
Derivative liability movement     1,526,191       (7,582,110 )
Foreign exchange movements     (34,301 )     (175,500 )
Net (loss) income before taxation     (1,854,306 )     3,084,992  
Taxation     280,903           
Net (loss) income     (1,573,403 )     3,084,992  
Net loss attributable to non-controlling interest     30,457           
Net (loss) income attributable to Ethema Health Corporation Stockholders’     (1,542,946 )     3,084,992  
Preferred stock dividend     (100,584 )     (52,888 )
Net (loss) income available to common shareholders of Ethema Health Corporation     (1,643,530 )     3,032,104  
Accumulated other comprehensive income                
Foreign currency translation adjustment     9,813       78,743  
                 
Total comprehensive (loss) income   $ (1,633,717 )   $ 3,110,847  
                 
Basic (loss) income per common share   $ 0.00     $ 0.00  
Diluted (loss) income per common share   $ 0.00     $ 0.00  
Weighted average common shares outstanding – Basic     2,701,590,443       1,594,016,327  
Weighted average common shares outstanding – Diluted     2,701,590,443       2,045,373,732  

 

The accompanying notes are an integral part of the consolidated financial statements

 

 

F-3

 

ETHEMA HEALTH CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

 

 

                                                                                 
    Series A Preferred   Common   Additional Paid   Discount   Comprehe   Accumul   Non-controlling    
    Shares   Amount   Shares   Amount   in Capital   to par value   nsive Income   ated Deficit   ders interest   Total
                                         
Balance as of December 31, 2019            $          155,483,897     $ 1,554,838     $ 23,188,527     $        $ 727,976     $ (45,491,885 )            $ (20,020,544 )
Shares issued for commitment fees     —                  2,700,000       27,000       138,780                                           165,780  
Warrants exercised     —                  184,000,000       1,840,000                (1,744,132 )                                95,868  
Conversion of convertible notes     —                  1,586,659,618       15,866,597                (14,729,336 )                                1,137,261  
Settlement of liabilities     —                  100,000,000       1,000,000                (1,255,311 )                       700,000       444,689  
Settlement of liabilities, related party     4,000,000       40,000       —                                                               40,000  
Cancelation of shares     —                  (1,757,850 )     (17,578 )     17,578                                               
Foreign currency translation     —                  —                                    78,743                         78,743  
Net income     —                  —                                            3,084,992                3,084,992  
Dividends accrued     —                  —                                             (52,888 )              (52,888 )
Balance as of December 31, 2020     4,000,000     $ 40,000       2,027,085,665     $ 20,270,857     $ 23,344,885     $ (17,728,779 )   $ 806,719     $ (42,459,781 )     700,000     $ (15,026,099 )
Warrants exercised     —                  280,625,762       2,806,258       (2,806,258 )                                             
Shares issued in consideration of acquisition of subsidiary     —                  100,000,000       1,000,000                (590,000 )                                410,000  
Fair value of non-controlling interest on acquisition of subsidiary     —                  —                                                      153,333       153,333  
Conversion of convertible notes     —                  1,171,342,378       11,713,424       97,000       (7,694,588 )                                4,115,836  
Fair value of warrants issued to convertible debt holders     —                  —                  1,762,266                                           1,762,266  
Fair value of beneficial conversion feature of convertible debt issued     —                  —                  133,750                                           133,750  
Foreign currency translation     —                  —                                    9,813                         9,813  
Transactions with related parties     —                  —                  259,707                                       259,707  
Net loss     —                  —                                            (1,542,946 )     (30,457 )     (1,573,403 )
Dividends accrued     —                  —                                             (100,584 )              (100,584 )
Balance as of December 31, 2021     4,000,000     $ 40,000       3,579,053,805       35,790,539       22,791,350       (26,013,367 )     816,532       (44,103,311 )     822,876       (9,855,381 )

 

 

The accompanying notes are an integral part of the consolidated financial statement

 

F-4

 

ETHEMA HEALTH CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS 

 

 

                 
   

Year ended

December 31,

2021

 

Year ended

December 31,

2020

Operating activities                
Net (loss) income   $ (1,573,403 )   $ 3,084,992  
Adjustment to reconcile net (loss) income to net cash used in operating activities:                
Depreciation and amortization expense     325,350       121,276  
Fair value of warrants granted     854,140           
Gain on debt extinguishment              (12,601,823 )
Gain on disposal of property              (36,470 )
Forgiveness of federal relief loan     (156,782 )         
Stock based compensation for services              165,780  
Amortization of debt discount     1,960,551       861,657  
Derivative liability movements     (1,526,191 )     7,582,110  
Non-cash interest converted to equity     90,144       45,208  
Non-cash interest income              (23 )
Exercise of warrants              95,868  
Amortization of right of use asset     118,745           
Deferred taxation movement     (37,588 )         
Unrealized foreign exchange loss              141,927  
Movement in bad debt reserve              (2,734 )
Changes in operating assets and liabilities                
Accounts receivable     4,267       105,561  
Prepaid expenses     10,461       1,521  
Other current assets     114,704       (11,938 )
Accounts payable and accrued liabilities     25,108       301,035  
Operating lease liabilities     (101,637 )         
Taxes payable     (193,436 )     44,083  
Net cash used in operating activities     (85,567 )     (101,970 )
Investing activities                
Acquisition of subsidiary, net of cash     10,324           
Deposits refunded              5,995  
Other investments     (450,537 )     (690,449 )
Purchase of property and equipment     (132,832 )         
Net cash used in investing activities     (573,045 )     (684,454 )
                 
Financing activities                
Decrease in bank overdraft              (11,079 )
Repayment of mortgage     (117,515 )     (105,952 )
Proceeds from convertible notes     1,232,700       1,129,050  
Repayment of convertible notes     (499,544 )     (210,600 )
Proceeds from promissory notes     420,449           
Repayment of promissory notes     (464,338 )     (150,583 )
Proceeds from government assistance loans     173,322       186,600  
Preferred stock dividends paid     (24,000 )     (37,818 )
Repayment of third party loans     (127,640 )         
Proceeds from finance leases     43,449           
Repayment of finance leases     (3,168 )         
(Repayment) Proceeds from related party notes     (43,520 )     54,401  
Net cash provided by financing activities     590,195       854,019  
                 
Effect of exchange rate on cash     26,739       19,930  
                 
Net change in cash     (41,678 )     87,525  
Beginning cash balance     90,500       2,975  
Ending cash balance   $ 48,822     $ 90,500  
                 
Supplemental cash flow information                
Cash paid for interest   $ 281,153     $ 180,668  
Cash paid for income taxes   $        $     
                 
Non-cash investing and financing activities                
Fair value of warrant issued   $ 1,762,266     $     
Shares issued in consideration of acquisition of subsidiary   $ 410,000     $     
Conversion of convertible notes   $ 4,115,836     $ 1,137,261  
Conversion of related party payable to common stock   $        $ 25,000  
Conversion of related party payable to Series A Preferred stock   $        $ 40,000  
Settlement of liabilities   $        $ 844,689  
Fair value of non-controlling interest   $ 153,333     $     

 

  

The accompanying notes are an integral part of the consolidated financial statements

F-5

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

1. Nature of business

 

 

Since 2010, the Company has operated addiction treatment centers. Initially the Company operated an addiction treatment center in Ontario Canada under its Greenestone Muskoka clinic, which was sold on February 14, 2017. Simultaneously with this sale the Company purchased buildings and operated an addiction treatment center in Delray Beach Florida under its Addiction recovery Institute of America subsidiary with a license obtained in December 2016, initially though owned properties in Delray Beach and subsequently though leased properties in West Palm Beach, Florida. Since June 30, 2020, the Company has been actively involved in the management of a treatment center operated by Evernia in West Palm Beach Florida. On July 1, 2021, the Company closed on the acquisition of 75% of ATHI, which owns 100% of Evernia, once the probationary approval of a license was obtained from the Department of Children and Family Services of Florida. Evernia is the only active treatment center operated by the Company.

 

The Company also owns the real estate on which its Greenstone Muskoka clinic operated. The current tenant operates an addiction treatment center on these premises. The Company collects rent on this property, which is treated as a separate business segment. 

 

F-6

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

   

2. Summary of significant accounting policies

 

Financial Reporting

 

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

 

Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company’s system of internal accounting control is designed to assure, among other items, that i) recorded transactions are valid; ii) valid transactions are recorded; and iii) transactions are recorded in the proper period in a timely manner to produce financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

 

  a) Use of Estimates

 

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

 

  b) Principals of consolidation and foreign currency translation

 

The accompanying consolidated financial statements include the accounts of the Company and all of its subsidiaries. All intercompany transactions and balances have been eliminated on consolidation.

 

Certain of the Company’s subsidiaries functional currency is the Canadian dollar, while the Company’s reporting currency is the U.S. dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign Currency Translation” as follows:

 

  Monetary assets and liabilities at the rate of exchange in effect at the balance sheet date.

 

  Certain non-monetary assets and liabilities and equity at historical rates.

 

  Revenue and expense items and cash flows at the average rate of exchange prevailing during the year.

 

Adjustments arising from such translations are deferred until realization and are included as a separate component of stockholders’ deficit as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in determining net income (loss) but reported as other comprehensive income (loss).

 

For foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange transaction gain or loss results which is included in determining net income for the year.

 

The relevant translation rates are as follows: For the year ended December 31, 2021, a closing rate of CDN$1 equals US$0.7888 and an average exchange rate of CDN$1 equals US$0.7977, for the year ended December 31, 2020, a closing rate of CDN$1.0000 equals US$0.7854 and an average exchange rate of CDN$1.0000 equals US$0.7455.

 

  c) Business Combinations

 

The Company allocates the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed for business combinations with third parties based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill.

 

Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired users, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates.

 

 

F-7

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

    

2. Summary of significant accounting policies (continued)

 

  d) Cash and cash equivalents

 

For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institution in the USA and Canada. There were no cash equivalents at December 31, 2021 and 2020.

 

The Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which are insured by the Federal Deposit Insurance Corporation up to a limit of $250,000 per institution, in Canada which are insured by the Canadian Deposit Insurance Corporation up to a limit of CDN$100,000 per institution.

 

  e) Accounts receivable

 

Accounts receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s consolidated financial statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.

 

  f) Allowance for Doubtful Accounts, Contractual and Other Discounts

 

The Company derives the majority of its revenues from commercial payors at in-network rates. Management estimates the allowance for contractual and other discounts based on its historical collection experience and contractual rates. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account is written off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.

 

  g) Property and equipment

 

Property and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset.

 

  h) Intangible assets

 

Intangible assets are stated at acquisition cost less accumulated amortization, if applicable, less any adjustments for impairment losses.

 

Amortization is charged on a straight-line basis over the estimated remaining useful lives of the individual intangibles. Where intangibles are deemed to be impaired the Company recognizes an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.

 

Licenses to provide substance abuse rehabilitation services are amortized over the expected life of the contract, including any anticipated renewals. The Company expects its licenses to remain in operation for a period of five years.

   

 

F-8

 

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

    

2. Summary of significant accounting policies (continued)

 

  i) Leases

 

The Company accounts for leases in terms of AC 842 whereby leases are classified as either finance or operating leases. Leases that transfer substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as finance leases. At the time a finance lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition and financing. Property and equipment recorded under finance leases is amortized on the same basis as described above. Operating leases are recognized on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more than twelve months. Payments under operating leases are expensed as incurred.

 

  j) Derivatives

 

The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. The Company uses a Black Scholes Option Pricing model to estimate the fair value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives during each reporting period are included in the statements of operations. Inputs into the Black Scholes Option Pricing model require estimates, including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life of the financial instruments being fair valued.

 

If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature.

 

  k) Financial instruments

 

The Company initially measures its financial assets and liabilities at fair value, except for certain non-arm’s length transactions. The Company subsequently measures all its financial assets and financial liabilities at amortized cost.

 

Financial assets measured at amortized cost include cash and accounts receivable.

 

Financial liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, harmonized sales tax payable, withholding taxes payable, convertible notes payable, loans payable and related party notes.

 

Financial assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted by the transaction costs that are directly attributable to their origination, issuance or assumption.

 

FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

●     Level 1. Observable inputs such as quoted prices in active markets;
●  Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.

 

The Company measures its convertible debt and derivative liabilities associated therewith at fair value. These liabilities are revalued periodically and the resultant gain or loss is realized through the Statement of Operations and Comprehensive Loss.

 

  l) Related parties

 

Parties are considered to be related to the Company if the parties directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged.

 

F-9

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

    

2. Summary of significant accounting policies (continued)

 

  m) Revenue Recognition

 

ASC 606 requires companies to exercise more judgment and recognize revenue using a five-step process.

 

The Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the consolidated statements of operations and comprehensive loss.

 

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.

 

The Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component.

 

The Company derives a significant portion of its revenue from other payors that receive discounts from established billing rates. The various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.

 

Settlements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s receivables were $176,011and $3,075 at December 31, 2021 and December 31, 2020, respectively. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount.

 

The Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions:

 

  i. identify the contract with a customer;
  ii. identify the performance obligations in the contract;
  iii. determine the transaction price;
  iv. allocate the transaction price to performance obligations in the contract; and
  v. recognize revenue as the performance obligation is satisfied.

 

  n) Income taxes

 

The Company accounts for income taxes under the provisions of ASC Topic 740, “Income Taxes”. Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes are provided using the liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The tax basis of an asset or liability is the amount attributed to that asset or liability for tax purposes. The effect on deferred taxes of a change in tax rates is recognized in income in the period of change. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion of, or all of, the deferred tax assets will not be realized.

 

ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax return. The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company recognizes interest and penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses in the period that such determination is made. The tax returns for fiscal 2018, through 2020 are subject to audit or review by the US tax authorities, whereas fiscal 2010 through 2020 are subject to audit or review by the Canadian tax authority.

 

F-10

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

    

2. Summary of significant accounting policies (continued)

 

  o) Net income (loss) per Share

 

Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the year.

 

Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.

 

Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share). 

 

  p) Stock based compensation

 

Stock based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the year ended December 31, 2021 and 2020 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with performance conditions and no awards dependent on market conditions.

 

  q) Financial instruments Risks

 

The Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s risk exposure and concentrations at the balance sheet date, December 31, 2021 and 2020.

 

  i. Credit risk

 

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable.

 

Credit risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located in the US.

 

In the opinion of management, credit risk with respect to accounts receivable is assessed as low.

 

  ii. Liquidity risk

 

Liquidity risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity risk through its working capital deficiency of $13,245,003, which includes derivative liabilities of $515,901, and an accumulated deficit of $44,103,311. The Company is dependent upon the raising of additional capital in order to implement its business plan. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. In the opinion of management, liquidity risk is assessed as high, material and remains unchanged from that of the prior year.

 

F-11

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

   

2. Summary of significant accounting policies (continued)

 

  q) Financial instruments Risks (continued)

 

  iii. Market risk

 

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest rate risk and currency risk.

 

  a. Interest rate risk

 

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its convertible debt, mortgage loans, short term loans, third party loans and government assistance loans as of December 31, 2021. In the opinion of management, interest rate risk is assessed as moderate.

 

  b. Currency risk

 

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to fluctuations in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated in Canadian dollars. Based on the net exposures at December 31, 2021, a 5% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an approximate $6,187 increase or decrease in the Company’s after tax net income from operations. The Company has not entered into any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged from that of the prior year.

 

  c. Other price risk

 

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion of management, the Company is not exposed to this risk and remains unchanged from the prior year.

   

  r) Recent accounting pronouncements

 

In November 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Disclosures by Entities about Government Assistance (Topic 832), the update increases the transparency of government assistance, including the following disclosures: (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements.

 

This ASU is effective for fiscal years beginning after December 15, 2021.

 

The effects of this ASU on the Company’s consolidated financial statements is currently being assessed and is not expected to have an impact on current disclosure.

 

The FASB issued several additional updates during the period, none of these standards are either applicable to the Company or require adoption at a future date and none are expected to have a material impact on the consolidated financial statements upon adoption.

 

  s) Comparative and prior period disclosures

 

The comparative and prior period disclosed amounts presented in these consolidated financial statements have been reclassified where necessary to conform to the presentation used in the current year and period.

F-12

 

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

  

3. Going concern

 

The Company’s consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations in the normal course of business. At December 31, 2021 the Company has a working capital deficiency of $13.2 million, 13.2 million including derivative liabilities of $0.5 million 515,901 and total liabilities in excess of assets in the amount of $9.5 million . Management believes that current available resources will not be sufficient to fund the Company’s planned expenditures over the next 12 months. Accordingly, the Company will be dependent upon the raising of additional capital through placement of common shares, and/or debt financing in order to implement its business plan and generating sufficient revenue in excess of costs. If the Company raises additional capital through the issuance of equity securities or securities convertible into equity, stockholders will experience dilution, and such securities may have rights, preferences or privileges senior to those of the holders of common stock or convertible senior notes. If the Company raises additional funds by issuing debt, the Company may be subject to limitations on its operations, through debt covenants or other restrictions. If the Company obtains additional funds through arrangements with collaborators or strategic partners, the Company may be required to relinquish its rights to certain geographical areas, or techniques that it might otherwise seek to retain. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. These consolidated financial statements do not include any adjustments to the amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

 

4. Acquisition of subsidiaries

 

On June 30, 2020, the Company entered into a stock purchase agreement to acquire 51% of American Treatment Holdings, Inc. (“ATHI”) from The Q Global Trust (“Seller”) and Lawrence B Hawkins (“Hawkins”), which in turn owns 100% of Evernia Health Services LLC. (“Evernia”), which operates drug rehabilitation facilities. The consideration for the acquisition is a loan to be provided by the purchaser to Evernia in the amount of $500,000. As of the date of acquisition, July 1, 2021, the Company had advanced Evernia $1,140,985.

 

The Company originally had a 180 day option, from the advancement of the first tranche to Evernia, to purchase an additional 9% of ATHI for a purchase consideration of $50,000.

 

On April 28, 2021, the Stock Purchase Agreement was amended whereby the option to purchase an additional 9% of ATHI for $50,000 was amended to purchase an additional 24%, an increase of 15% over the prior option, for 100,000,000 shares of common stock. The remaining condition to closing, the receipt of approval for the change of ownership of the license from the Department of Children and Family Services of Florida, was satisfied by the probationary approval, which was received on June 30, 2021. The Company exercised the option and issued the 100,000,000 shares of common stock and $50,000. As of December 31, 2021, the Company had issued the 100,000,000 shares of common stock and had paid $42,750 due to the Seller, in terms of the amended agreement. In addition to the consideration paid for the additional equity the Company agreed to execute a promissory note for the payment of any unpaid management fees at the time of Closing such that the unpaid fees shall be paid pari-passu with the repayment of the Loan Agreement and Seller agrees that any funds advanced to the Company by Behavioral Health Holdings, LLC shall be forgiven and considered contributed capital to ATHI. The Company agrees to advance up to $1,100,000 under the Loan Agreement for the funding of the operations of ATHI as required without any contribution required by the Seller. 

 

Pursuant to the terms of the Amended Purchase Agreement, the consideration paid for 75% of the equity of ATHI was $50,000 in cash plus the issuance of 100,000,000 shares of the Company’s common stock with a market value of $410,000 on the date of acquisition.

 

In terms of the agreement, the preliminary purchase price was allocated to the fair market value of tangible and intangible assets acquired and liabilities assumed as follows:

 

 Schedule of intangible assets acquired and liabilities assumed    
    Amount
Consideration        
Cash   50,000  
100,000,000 shares of common stock at fair market value     410,000  
Total purchase consideration   $ 460,000  
Recognized amounts of identifiable assets acquired and liabilities assumed        
Cash   60,324  
Other Current assets     198,133  
Property, plant and equipment     130,234  
Right of use asset     1,772,560  
Intangibles     1,789,903  
 Total assets     3,951,154  
Less: liabilities assumed        
Current liabilities assumed     (50,040 )
Advances     (1,140,985 )
Operating lease liabilities assumed     (1,836,151 )
Imputed Deferred taxation on identifiable intangible acquired     (310,645 )
 Total liabilities     (3,337,821 )
Net identifiable assets acquired and liabilities assumed     613,333  
Fair value of non-controlling interest     (153,333 )
Total   $ 460,000  

F-13

 

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

  

4. Acquisition of subsidiaries (continued)

 

The amount of revenue and earnings include in the Company’s consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2021 and the revenue and earnings of the combined entity had the acquisition date been January 1, 2020. Evernia only began operations in June 2020, therefore earning were included from June 2020.

 

 Schedule of revenue and earnings        
    Revenue   Earnings
         
Actual from July 1, 2021 to December 31, 2021   $ 1,568,071     $ (115,142 )
                 
2021 Supplemental pro forma from January 1, 2021 to December 31, 2021   $ 3,024,297     $ (1,965,484 )
                 
2020 Supplemental pro forma from inception to December 31, 2020   $ 420,996     $ 2,142,531  

 

The 2021 and 2020 Supplemental pro forma earnings information was adjusted to account for amortization of intangibles on acquisition of $178,990 and $357,981, respectively.

 

5. Other current assets

 

Other current assets includes the following:

 

On February 25, 2019, the Company entered into a Letter of Intent whereby it would purchase a 33.33% interest in Local Link Wellness, LLC (“LLW”) for gross proceeds of $400,000. LLW proposed to provide a comprehensive addiction treatment program to large employee groups. The Company had advanced LLW a total of $120,000 at September 30, 2021. These funds were advanced as short-term promissory notes that were immediately due and payable.

 

The Company has no intention to close on the purchase of LLW, and management recorded a full reserve against this advance as they believe it is not recoverable.

 

6. Other investments

  

On June 30, 2020, the Company entered into an agreement to acquire 51% of American Treatment Holdings, Inc. (“ATHI”) from The Q Global Trust (“Seller”) and Lawrence B Hawkins (“Hawkins”), which in turn owns 100% of Evernia Health Services LLC. (“Evernia”), which operates drug rehabilitation facilities. The consideration for the acquisition is a loan to be provided by the purchaser to Evernia in the amount of $500,000. As of December 31, 2020, the Company had advanced Evernia $690,449.

 

The Company originally had a 180 day option, from the advancement of the first tranche to Evernia, to purchase an additional 9% of ETHI for a purchase consideration of $50,000.

 

On April 28, 2021, the Stock Purchase Agreement date June 30, 2020 between the Company and the Q Global Trust, and ATHI was amended whereby the option to purchase an additional 9% of ATHI for $50,000 was amended to purchase an additional 24%, an increase of 15% over the prior option, for 100,000,000 shares of common stock. The remaining condition to closing, the receipt of approval for the change of ownership of the license from the Department of Children and Family Services of Florida, was satisfied by the probationary approval, which was received on June 30, 2021. The Company exercised the option and issued the 100,000,000 shares of common stock and paid $42,750 of the $50,000 due to the Seller as of December 31, 2021. In addition to the consideration paid for the additional equity the Company agreed to execute a promissory note for the payment of any unpaid management fees at the time of Closing such that the unpaid fees shall be paid pari-passu with the repayment of the Loan Agreement and Seller agrees that any funds advanced to the Company by Behavioral Health Holdings, LLC shall be forgiven and considered contributed capital to ATHI. The Company agrees to advance up to $1,100,000 under the Loan Agreement for the funding of the operations of ATHI as required without any contribution required by the Seller. 

 

F-14

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

6. Other investments (continued)

  

On June 30, 2020, the Company entered into an agreement to acquire 51% of Behavioral Health Holdings, Inc. (“BHHI”) from The Q Global Trust (“Seller”) and Lawrence B Hawkins, which in turn owns 100% of Peace of Mind Counseling Services, Inc. (“PMCS”), which operates drug rehabilitation facilities. During 2021, the Company decided not to pursue the acquisition of BHHI.

 

7. Due on sale of subsidiary

  

On February 14, 2017, the Company sold its Canadian Rehab Clinic for gross proceeds of CDN$10,000,000, of which CDN$1,500,000 had been retained in an escrow account for a period of up to two years in order to guarantee the warranties provided by the Company in terms of the APA. As of December 31, 2021, CDN$1,055,042 of the escrow had been refunded to the Company and CDN$461,318 had been used to affect building improvements to the premises owned by CCH, for a total reduction of CDN$1,516,360. The remaining escrow balance was CDN$6,485 (approximately US$ 5,115).

 

8. Property and equipment

  

Property and equipment consists of the following:  

 

 

 Schedule of sale of property   December 31,
2021
  December 31, 2020
    Cost   Accumulated depreciation   Net book value   Net book value
Land   $ 169,585     $        $ 169,585     $ 168,866  
Property     3,208,034       (611,444 )     2,596,590       2,713,354  
Leasehold improvements     166,195       (12,465 )     153,730           
Furniture and fittings     51,518       (9,378 )     42,140           
Vehicles     55,949       (6,681 )     49,268           
Computer equipment     1,450       (100 )     1,350           
    $ 3,652,731     $ (640,070 )   $ 3,012,663     $ 2,882,220  

 

Depreciation expense for the year ended December 31, 2021 and 2020 was $146,360 and $121,276, respectively.

 

F-15

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

  

9. Intangibles

 

Intangible assets consist of the Company’s preliminary estimate of the fair value of intangibles acquired with the acquisition of ATHI disclosed in Note 4 above. The Company preliminarily allocated the excess over the tangible assets acquired, less the liabilities assumed to the contract provided to the Company by a health care service provider.

 

Intangible assets consist of the following:  

 

 Schedule of Intangible assets   December 31,
2021
    Cost   Accumulated amortization   Net book value
Health care Provider license   $ 1,789,903     $ 178,990     $ 1,610,913  
                         

 

The Company evaluates intangible assets for impairment on an annual basis during the last month of each year and at an interim date if indications of impairment exist. Intangible asset impairment is determined by comparing the fair value of the asset to its carrying amount with an impairment being recognized only when the fair value is less than carrying value and the impairment is deemed to be permanent in nature.

 

The Company recorded $178,990 in amortization expense for finite-lived assets for the year ended December 31, 2021.

 

10. Leases

 

The Company acquired ATHI on July 1, 2021, ATHI’s wholly owned subsidiary had entered into an operating lease agreement for certain real property located at 1590 S. Congress Avenue, West Palm Beach, Florida, with effect from February 1, 2019 for a period of three years, expiring on 1 February 2022. Under the terms of the lease agreement, the lease was extended during October 2021 for a further 5 year period until 1 February 2027.

 

To determine the present value of minimum future lease payments for operating leases at February 1, 2019, the Company was required to estimate a rate of interest that we would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment (the "incremental borrowing rate" or "IBR").

 

The Company determined the appropriate IBR by identifying a reference rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference rate, the Company used the average of (i) the five year ARM interest rate as quoted by Freddie Mac adjusted for a risk premium of 20%. The Company determined that 4.64% per annum was an appropriate incremental borrowing rate to apply to its real-estate operating lease.

 
Right of use assets are included in the consolidated balance sheet are as follows:

 

 Schedule of Right of use assets                
    December 31,
2021
  December 31,
2020
Non-current assets                
Right-of-use assets – finance leases, net of depreciation, included in Property and equipment   $ 49,268     $     
Right-of-use assets - operating leases, net of amortization   $ 1,653,816     $     

  

Lease costs consists of the following: 

 

 Schedule of Lease costs                
    Year ended December 31,
    2021   2020
 Finance lease cost:                
Amortization of right-of-use assets   $ 6,681     $     
Interest expense on finance lease liabilities     1,367           
Finance lease cost     8,048           
                 
Operating lease cost   $ 178,679     $ 5,512  
Lease cost   $ 186,727     $ 5,512  

 

 

F-16

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

10. Leases (continued)

 

Other lease information: 

 Schedule of Other lease                
    Year ended December 31,
    2021   2020
Cash paid for amounts included in the measurement of lease liabilities        
Operating cash flows from finance leases   $ (1,367 )   $     
Operating cash flows from operating leases     (160,272 )     (5,512 )
Financing cash flows from finance leases     40,281           
Cash paid for amounts included in the measurement of lease liabilities   $ (121,358 )   $ (5,512 )
                 
Weighted average lease term – finance leases     4 years and ten months       —    
Weighted average remaining lease term – operating leases     5 years and 1 months       —    
                 
Discount rate – finance leases     6.61 %     —    
Discount rate – operating leases     4.64 %     —   %

 

Maturity of Leases

 

Finance lease liability

 

The amount of future minimum lease payments under finance leases as of December 31, 2021 is as follows:

 

 Schedule of Finance lease liability        
    Amount
2022   $ 9,829  
2023     9,829  
2024     9,829  
2025     9,829  
2026     7,902  
Total undiscounted minimum future lease payments     47,218  
Imputed interest     (6,937 )
Total finance lease liability   $ 40,281  
Disclosed as:        
Current portion   $ 7,386  
Non-Current portion     32,895  
Lease liability   $ 40,281  

 

Operating lease liability

 

The amount of future minimum lease payments under operating leases are as follows:

 

 Schedule of Operating lease liability    
    Amount
     
2022   $ 332,073  
2023     348,677  
2024     366,110  
2025     384,416  
2026     437,407  
Total undiscounted minimum future lease payments     1,868,683  
Imputed interest     (134,169 )
Total operating lease liability   $ 1,734,514  
         
Disclosed as:        
Current portion   $ 241,083  
Non-Current portion     1,493,431  
 Lease liability   $ 1,734,514  

  

F-17

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

11. Taxes Payable

 

Taxes payable consist of:

 

A payroll tax liability of $144,021 (CDN$182,589) in Greenestone Muskoka which has not been settled as yet.

 

A GST/HST tax payable of $123,134 (CDN$156,109).

 

The Company has assets and operates businesses in Canada and is required to disclose these operations to the US taxation authorities, the requisite disclosure has not been made. Management has reserved the maximum penalty due to the IRS in terms of non-disclosure. This noncompliance with US disclosure requirements is currently being addressed. Previously an amount of $250,000 was accrued for any potential exposure, this accrual has been reversed in the current year.

 

 Schedule of taxation payable                
    December 31,
2021
  December 31,
2020
         
Payroll taxes   $ 144,020     $ 143,410  
HST/GST payable     123,134       73,503  
US penalties due              250,000  
Income tax payable     391,682       383,364  
 Taxes Payable   $ 658,836     $ 850,277  

 

12. Short-term Convertible Notes

 

The short-term convertible notes consist of the following:

 

Schedule of short-term convertible notes                                                    
    Interest rate   Maturity Date   Principal   Interest   Debt Discount   December 31, 2021   December 31, 2020
Leonite Capital, LLC     8.5 %     $        $        $        $        $ 70,583  
      12.0 %    On Demand     278,629       36,950                315,579       147,058  
                                                     
First Fire Global Opportunities Fund     6.5 %   October 29,2021                                         25,297  
                                                     
Auctus Fund, LLC     0.0 %   On Demand     100,000                         100,000       150,000  
      10.0 %   August 13, 2021                                         40,202  
                                                     
Labrys Fund, LP     12.0 %   November 30, 2021              8,826                8,826       26,159  
      11.0 %   May 7, 2022     543,671                (189,167 )     354,504           
      11.0 %   June 2, 2022     230,000       14,899       (96,411 )     148,488           
                                                     
Ed Blasiak     6.5 %   September 14, 2021     55,000       4,697                59,697       17,347  
                                                     
Joshua Bauman     6.5 %   September 14, 2021                                         43,247  
      11.0 %   October 21, 2022     150,000       3,210       (120,823 )     32,387           
                                                     
Geneva Roth Remark Holdings, Inc.     9.0 %   August 29, 2021                                         19,238  
      9.0 %   October 15, 2021                                         6,753  
      9.0 %   January 3, 2022                                             
      8.0 %   October 1, 2022     74,044       5,924       (55,584 )     24,384           
                                                     
Series N convertible notes     6.0 %   On Demand     3,229,000       619,073                3,848,073       3,654,333  
                                                     
                 $ 4,660,344      $ 693,579      $ (461,985 )   $ 4,891,938     $ 4,200,217  

 

 

F-18

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

  

12. Short-term Convertible Notes (continued)

 

Leonite Capital, LLC

 

Convertible Promissory Notes

 

 Effective March 19, 2019, the Company entered into a note extension agreement with Leonite, whereby the convertible notes outstanding to Leonite, amounting to $2,420,000, for consideration of $75,000 added to the principal outstanding on the note on January 1, 2019, a further $75,000 added to the principal outstanding on the note on February 1, 2019 and a further $100,000 added to the principal of the note on March 15, 2019, the maturity date of all of the convertible notes above were extended to December 31, 2019 and has subsequently been partially settled by the transfer of the property located at 810 Andrews Avenue, Delray Beach, Florida, valued at $1,500,000.

 

On August 26, 2019, the Company, entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $60,000, including an Original Issue Discount of $10,000, for net proceeds of $47,000. The note had a maturity date of September 10, 2019 and bears interest at 1.0% per annum. The outstanding principal amount of the note is convertible at any time and from time to time at the election of the purchaser following the issue date into shares of the Company’s common stock at a conversion price equal to $0.06 per share subject to price protection and anti-dilution protection. In conjunction with this note the Company issued a five year warrant to purchase 1,000,000 shares of common stock at an exercise price of $0.10 per share, subject to anti-dilution and price protection.

 

On October 10, 2019, the Company transferred a warranty deed to the real property located at 810 Andrews Avenue, Delray Beach, Florida to Leonite Capital LLC, in settlement of indebtedness of $1,398,514 and additional expenses related to the disposal of the property of $36,470. These expenses of $36,470 were provided for resulting in net proceeds recognized on the transfer of the property of $1,362,044.

 

On July 12, 2020, the company entered into a debt extinguishment agreement with Leonite whereby the following occurred:

 

  1. The total amount outstanding under the Leonite note, including principal and interest was reduced to $150,000
  2. $700,000 of the note was converted into Series A Redeemable Preferred shares in the Company’s subsidiary, Cranberry Cove Holdings, accruing dividends at 10% per annum.
  3. $400,000 of the note was converted into series B Preferred stock in the Company for a 12 month period, mandatorily redeemable by the Company accruing dividends at 6% per annum payable in cash or stock, subject to certain conditions.
  4. The remaining balance of $150,000 will accrue interest at 8.5% per annum and is convertible into common stock and repayable in 6 monthly installments of $25,000 commencing after December 12, 2020.
  5. The existing warrants were cancelled and a new five year warrant, with a cashless exercise option, exercisable for a minimum of 326,286,847 shares of common stock and a maximum of 20% of the outstanding equity of the Company at an initial exercise price of $0.10 per share subject to adjustment based on new stock issuances or the lowest volume weighted exercise price of the stock for 30 days immediately preceding the exercise was issued to Leonite.

 

On December 28, 2020, Leonite converted $80,000 plus accrued interest of $5,949 of the Leonite loan amended on July 12, 2020, into 96,331,811 shares of common stock at a conversion price of $0.0009, thereby realizing a loss on conversion of $240,616. On January 8, 2021, Leonite converted the remaining principal amount of $70,000, plus accrued interest thereon of $137, into 78,763,466 shares of common stock at a conversion price of $0.0009 per share.

 

 

F-19

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

  

12. Short-term Convertible Notes (continued)

 

Leonite Capital, LLC (continued)

 

Convertible Promissory notes (continued) 

 

On July 12, 2020, the Company entered into a Senior Secured Convertible Note agreement with Leonite for $440,000 with an original issue discount of $40,000 for gross proceeds of $400,000, the initial tranche advanced will be for cash of $200,000 plus the OID of $20,000, the remaining advances will be at the discretion of the Leonite. The loan bears interest at 6.5% per annum and matures on June 12, 2021. The Company is required to make monthly payments of the accrued interest on the advances made. The note is convertible into common shares at the option of the holder at $0.10 per share, or 80% multiplied by the price per share paid in subsequent financings or after a six month period from the effective date at 60% of the lowest trading price during the preceding 21 consecutive trading days. The note has both conversion price protection and anti-dilution protection provisions.

 

On July 12, 2020, the Company entered into a five year option agreement with Leonite Capital LLC (“Leonite”) and other investors (collectively the “Transferees”), the Company agreed to sell to Leonite a portion of the total outstanding shares of ATHI from the shares of ATHI held by the company. The Company has provided Leonite an option to purchase 33% of ATHI from the Company for a purchase consideration of $0.0001 per share, based on the advances that Leonite made to the Company totaling $655,000. Leonite shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Leonite to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

In terms of clause 3.12 of the Senior secured convertible Promissory Note Agreement (“Leonite Note”) entered into with Leonite and the amendments thereto, the terms of the convertible promissory note issued to Labrys Fund LP on November 30, 2020, as described below, contained terms more favorable than those contained in the Leonite Note, resulting in an adjustment made to the Original issue discount of $4,000 and the issuance of five year warrants exercisable for 145,454,547 shares of common at an exercise price of $0.00205 per share, for all advances made to the Company by Leonite in terms of the Leonite Note, up to and including December 31, 2020.

 

On January 8, January 22, February 4, and February 19, 2021, Leonite advanced the company an aggregate cash amount of $290,000, including a revised original issue discount of $74,556 for an aggregate principal sum added to the Leonite Note of $364,556.

 

On March 3, 2021, in terms of a conversion notice, Leonite converted the principal sum of $82,681 and interest thereon of $12,319 of the Leonite Note into 97,000,000 shares of common stock at a conversion price of $0.0009 per share.

 

On June 1, 2021, in terms of a conversion notice, Leonite converted the principal sum of $25,084 and interest thereon of $4,166 of the Leonite Note into 30,000,000 shares of common stock at a conversion price of $0.0009 per share.

 

On June 10, 2021, in terms of a conversion notice, Leonite converted the principal sum of $58,908 and interest thereon of $342 of the Leonite Note into 60,000,000 shares of common stock at a conversion price of $0.0009 per share.

 

On September 10, 2021, in terms of a conversion notice, Leonite converted the principal sum of $59,260 and interest thereon of $1,718 of the Leonite Note into 59,259,630 shares of common stock at a conversion price of $0.0010 per share.

 

On October 19, 2021, in terms of a conversion notice, Leonite converted the principal sum of $44,444 and interest thereon of $5,302 of the Leonite Note into 50,496,728 shares of common stock at a conversion price of $0.0010 per share.

 

On October 29, 2021, the Company issued 83,771,947 shares of common stock to Leonite in connection with a conversion notice received, converting principal and interest of $83,022 at a conversion price of $0.0009 per share.

 

On November 22, 2021, in terms of a conversion notice, Leonite converted the principal sum of $50,532 and interest thereon of $7,145 of the Leonite Note into 58,427,091 shares of common stock at a conversion price of $0.0010 per share.

 

On December 13, 2021, in terms of a conversion notice, Leonite converted the principal sum of $89,684 and interest thereon of $249 of the Leonite Note into 90,682,696 shares of common stock at a conversion price of $0.0010 per share.

 

F-20

 

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

  

12. Short-term Convertible Notes (continued)

 

Power Up Lending Group LTD

 

On July 8, 2019, the Company entered into a Securities Purchase Agreement with Power Up, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $53,000. The Note had a maturity date of April 30, 2020 and bore interest at the rate of nine percent per annum from the date on which the Note was issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company had the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Power Up during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to 61% of the lowest closing bid price of the Company’s common stock for the ten trading days prior to conversion.

 

Between January 10, 2020 and January 24, 2020, in terms of conversion notices received, Power Up converted the aggregate principal amount of $53,000 and interest thereon of $1,085 into 75,618,509 shares of common stock at an average conversion price of $0.000715 per share.

 

On July 15 2019, the Company, entered into a Securities Purchase Agreement with Power Up, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $83,000. The Note has a maturity date of April 30, 2020 and bore interest at the rate of nine percent per annum from the date on which the Note was issued until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company had the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Power Up during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to 61% of the lowest closing bid price of the Company’s common stock for the ten trading days prior to conversion.

 

Between January 24, 2020 and February 27, 2020, in terms of conversion notices received, Power Up converted the aggregate principal amount of $41,400 into 453,800,493 shares of common stock at an average conversion price of 0.0000912 per share.

 

On June 1, 2020, The Company repaid the Power Up Lending Group $41,600 in full settlement of the convertible note entered into on July 15, 2019.

 

First Fire Global Opportunities Fund

 

On March 5, 2019, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $200,000, for net proceeds of $192,000 after the payment of legal fees and origination fees amounting to $8,000. The note had a maturity date of December 9, 2019. The outstanding principal amount of the note was convertible at any time and from time to time at the election of the purchaser. 180 days after the issued date into shares of the Company’s common stock at the lower of $0.08 per share or 65% of the lowest trade price during the ten consecutive trading days immediately prior to conversion. The note had certain buyback terms if the Company consummated a registered or unregistered primary offering of securities for capital raising purposes, or an option to convert at a 20% discount to the offering price to investors.

 

Between September 11, 2019 and December 30, 2019, in terms of a conversion notices received, the Company issued 11,887,445 shares of Common stock in settlement of $36,592 of principal outstanding.

 

Between January 6, 2020 and February 26, 2020, in terms of conversion notices received, First Fire converted an aggregate principal amount of $83,902 into 308,100,000 shares of common stock at an average conversion price of $0.000272 per share.

 

On June 3, 2020, the Company entered into an agreement with First Fire whereby the remaining balance of the convertible note of $73,006 would be settled by two payments of $25,000 each.

 

Between July 2, 2020 and August 17, 2020, the Company repaid the remaining principal outstanding of $50,000 plus additional interest charges of $1,500.

F-21

 

 

 

 

ETHEMA HEALTH CORPORATION

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

  

12. Short-term Convertible Notes (continued)

 

First Fire Global Opportunities Fund (continued)

 

On October 29, 2020, the Company entered into a Securities Purchase Agreement, pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $137,500, including an OID of $12,500. The note bears interest at 6.5% per annum and matures on October 29, 2021. The note is senior to any future borrowings and commencing on November 29, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding six month period.

 

On October 29, 2020, the Company entered into a five year option agreement with First Fire whereby the Company agreed to sell to First Fire a portion of the total outstanding shares of ATHI. The Company provided First Fire an option to purchase 6.25% of ATHI from the Company for a purchase consideration of $0.0001 per share, based on the advances that First Fire made to the Company totaling $125,000. First Fire shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by First Fire to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.

 

In terms of clause 3.12 of the Senior secured convertible Promissory Note Agreement (“First Fire Note”) entered into with First Fire, the terms of the convertible promissory note issued to Labrys Fund LP on November 30, 2020, as described below, contained terms more favorable than those contained in the First Fire Note, resulting in an adjustment made to the Original issue discount of $1,389 and the issuance of five year warrants exercisable for 50,505,051 shares of common at an exercise price of $0.00205 per share, for the advance made to the Company by First Fire in terms of the First Fire Note.

 

On May 10, 2021, the Company repaid the principal outstanding of $138,889, including interest and early settlement penalty thereon for the pay